Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Authors:
- W A DennyWDW A Denny
- S M PullenSPS M Pullen
- K M ThompsonKTK M Thompson
- A E LiALA E Li
- L H PattersonLPL H Patterson
- H H LeeHLH H Lee
- 1 July 1996
- journal article
- Vol. 27, S43-7
Abstract
Tertiary amine N-oxides of DNA intercalators with alkylamino sidechains are a new class of bioreductive drugs. N-oxidation masks the cationic charge of the amines, forming prodrugs with low DNA binding affinity and low toxicity which can be activated selectively by metabolic reduction under hypoxic conditions. This study compares three intercalator N-oxides (NC-NO, DACA-NO and AQ4N), which, respectively, give nitracrine (NC), DACA and AQ4 on reduction. In aerobic cell culture all three N-oxide were much less toxic than the corresponding amines, and showed large increases in cytotoxicity under hypoxia. The topoisomerase poisons DACA and AQ4 (and their N-oxides) were less active against non-cycling than cycling cells. However, only AQ4N was active against the mouse mammary tumour MDAH-MCa-4. This dialkylaminoanthraquinone-di-N-oxide has activity at least as great as the reference bioreductive drug RB 6145 against this tumour, both with and without radiation and when combined with the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA). It is suggested that the high in vivo activity of AQ4N relative to the other topoisomerase-targeted N-oxide, DACA-NO, may be in part due to release in hypoxic cells of an intracalator with sufficiently high DNA binding affinity that it is retained long enough to kill non-cycling cells when they eventually re-enter the cell cycle.Keywords
This publication has 12 references indexed in Scilit:
- Reductive Chemistry of the Novel Hypoxia-Selective Cytotoxin 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamideJournal of Medicinal Chemistry, 1995
- N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.1995
- Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acidInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994
- Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.1994
- Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agentCancer and Metastasis Reviews, 1993
- Bis-bioreductive agents as hypoxia-selective cytotoxins: Nitracrine N-oxideInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Selectivity of N-[2-(Dimethylamino)ethyl]acridine-4-car☐amide towards Lewis lung carcinoma and human tumour cell lines in vitroEuropean Journal of Cancer and Clinical Oncology, 1989
- Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamideJournal of Medicinal Chemistry, 1987
- Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cellsJournal of Medicinal Chemistry, 1986
- Hypersensitivity to cell killing and mutation induction by chemical carcinogens in an excision repair-deficient mutant of CHO cellsMutation Research/DNA Repair Reports, 1983